Sunday, June 21, 2026
🇺🇸 FDA

Patent directory · USPTO A61K / A61P

Browse patents

Browse 30,257 pharma-relevant patents (US A61K/A61P) linked to tracked companies, drugs, and pipeline programs.

Patents indexed 30,257
Companies 1,771
Drugs linked 4,798

Quick answer

NovaPharmaNews indexes 30,257 US pharmaceutical patents from USPTO PatentsView (CPC A61K/A61P), cross-linked to company assignees, drug INN profiles, and pipeline programs. Search by patent number, applicant, title, or CPC code — or use facet hubs for expiring patents, assignees, and therapeutic areas.

Patent results

Page 776 of 1,261

  1. US 8921340

    Methods for using synthetic triterpenoids in the treatment of bone or cartilage diseases or conditions

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Dec 30, 2014 · Expires Dec 25, 2034

    granted

  2. US 8921536

    HCV vaccines and methods for using the same

    Inovio Pharmaceuticals, Inc. · Granted Dec 30, 2014 · Expires Dec 25, 2034

    granted

  3. US 8921316

    Stable liquid VEGF antagonist formulations

    REGENERON PHARMACEUTICALS, INC. · Granted Dec 30, 2014 · Expires Dec 25, 2034

    granted

  4. US 8921050

    Methods of diagnosing renal cell carcinoma

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Dec 30, 2014 · Expires Dec 25, 2034

    granted

  5. US 8921372

    Inhibitors of hepatitis C virus

    Theravance Biopharma R&D IP, LLC · Granted Dec 30, 2014 · Expires Dec 25, 2034

    granted

  6. US 8921354

    Heterocyclic compound

    Takeda Pharmaceutical Company Limited · Granted Dec 30, 2014 · Expires Dec 25, 2034

    granted

  7. US 2014378455

    NEW USE OF 1H-INDAZOLE-3-CARBOXAMIDE COMPOUNDS AS GLYCOGEN SYNTHASE KINASE 3 BETA INHIBITORS

    ACRAF [IT] · Granted Dec 25, 2014 · Expires Dec 20, 2034

    granted

  8. US 8916565

    Pyrrolopyrazine-spirocyclic piperidine amides as modulators of ion channels

    Vertex Pharmaceuticals Incorporated · Granted Dec 23, 2014 · Expires Dec 18, 2034

    granted

  9. US 8916519

    Influenza A virus vaccines and inhibitors

    The Board of Regents of the University of Texas System · Granted Dec 23, 2014 · Expires Dec 18, 2034

    granted

  10. US 8916529

    Oligonucleotide-containing pharmacological compositions and their use

    Lakewood Amedex, Inc. · Granted Dec 23, 2014 · Expires Dec 18, 2034

    granted

  11. US 8916549

    Thienooxazepine derivative

    Takeda Pharmaceutical Company Limited · Granted Dec 23, 2014 · Expires Dec 18, 2034

    granted

  12. US 8916596

    Preventing or treating viral infection using an inhibitor of the LSD1 protein, a MAO inhibitor or an inhibitor of LSD1 and a MAO inhibitor

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Dec 23, 2014 · Expires Dec 18, 2034

    granted

  13. US 8916606

    Therapeutic compositions and methods for targeted delivery of active agents

    The Board of Regents of the University of Texas System · Granted Dec 23, 2014 · Expires Dec 18, 2034

    granted

  14. US 8916175

    Safer attenuated varicella-zoster virus vaccines with missing or diminished latency of infection

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Dec 23, 2014 · Expires Dec 18, 2034

    granted

  15. US 8916603

    Methods for treatment with bucindolol based on genetic targeting

    The Regents of the University of Colorado, a Body Corporate · Granted Dec 23, 2014 · Expires Dec 18, 2034

    granted

  16. US 8916580

    Spiro-oxindole compounds and their use as therapeutic agents

    Xenon Pharmaceuticals Inc. · Granted Dec 23, 2014 · Expires Dec 18, 2034

    granted

  17. US 8916693

    Monoconjugated chitosans as delivery agents for small interfering nucleic acids

    Nektar Therapeutics · Granted Dec 23, 2014 · Expires Dec 18, 2034

    granted

  18. US 8916566

    Pyridazinone compounds as phosphodiesterase inhibitors and methods of treating disorders

    Takeda Pharmaceutical Company Limited · Granted Dec 23, 2014 · Expires Dec 18, 2034

    granted

  19. US 8916556

    Pharmaceutical formulations comprising neurotrophin mimetics

    The United States of America represented by the Department of Vetran Affairs · Granted Dec 23, 2014 · Expires Dec 18, 2034

    granted

  20. US 8916551

    Heterocyclic compound and use thereof

    Takeda Pharmaceutical Company Limited · Granted Dec 23, 2014 · Expires Dec 18, 2034

    granted

  21. US 8916528

    Compositions containing resveratrol and nucleotides

    RESVERATROL PARTNERS, LLC · Granted Dec 23, 2014 · Expires Dec 18, 2034

    granted

  22. US 8916570

    A3 adenosine receptor agonists and antagonists

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Dec 23, 2014 · Expires Dec 18, 2034

    granted

  23. US 8916538

    Solid forms of a thiophosphoramidate nucleotide prodrug

    Vertex Pharmaceuticals Incorporated · Granted Dec 23, 2014 · Expires Dec 18, 2034

    granted

  24. US 8916197

    Bone marrow-directing drug delivery materials and their applications

    The Board of Regents of the University of Texas System · Granted Dec 23, 2014 · Expires Dec 18, 2034

    granted

Frequently asked questions

What patents are included in this directory?

We index 30,257 published US pharma-relevant patents filtered to CPC classes A61K and A61P, with assignee links to our company directory where a match exists.

How do I search for a patent?

Use the search box to match patent number, title, applicant name, or CPC classification (e.g. A61K). For cross-entity queries spanning news and drugs, use the global search.

How is this different from the patent intelligence dashboard?

The dashboard at /patents highlights expirations, recent grants, and assignee rankings. Browse is the full paginated directory with search — best for looking up a specific filing or applicant portfolio slice.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.